Valbiotis Terminate Licensing Agreement with Nestlé Health Science

Valbiotis has announced the termination of its licensing and supply agreement with Nestlé Health Science. This strategic shift allows Valbiotis to regain full intellectual property rights for TOTUM•63, a plant-based supplement targeting prediabetes and early stages of type 2 diabetes.

This decision follows Nestlé Health Science's refocused priorities in the health nutrition market. The agreement, effective May 31, 2024, transfers all patents and clinical data of TOTUM•63 to Valbiotis, including rights across 62 countries. No reimbursement of the 12.75 million Swiss francs provided by Nestlé Health Science is required.

With a cash position of €25 million as of December 2023, Valbiotis plans the direct launch of TOTUM•63 in France by early 2025 and seeks new international partnerships. The company continues to advance its other dietary supplements, TOTUM•854 and TOTUM•448, maintaining its strategic priorities.